^
Association details:
Biomarker:BCR-ABL1 fusion
Cancer:Acute Lymphocytic Leukemia
Drug Class:Tyrosine kinase inhibitor
Regimen:CVAD (cyclophosphamide + dexamethasone injection + doxorubicin hydrochloride + vincristine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

TYROSINE KINASE INHIBITORS PLUS HYPER-CVAD FOR THE FRONTLINE TREATMENT OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Published date:
11/26/2020
Excerpt:
In this study we observed that a high response rate can be achieved in predominantly young adults with Ph+ ALL treated with the Hyper-CVAD plus TKI.
DOI:
10.1016/j.htct.2020.10.316